Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts
Friedman–, Henry S. ; Houghton, Peter J. ; Schold, S. Clifford ; Keir, Stephen ; Bigner, Darell D.
Springer
Published 1994
Springer
Published 1994
| ISSN: |
1432-0843
|
|---|---|
| Source: |
Springer Online Journal Archives 1860-2000
|
| Topics: |
Medicine
|
| Notes: |
Abstract. The activity of dimethylaminomethyl-10-hydroxycamptothecin (topotecan) was evaluated against a panel of xenografts derived from ependymomas (D528 EP, D612 EP), childhood high-grade gliomas (D-456 MG, D-212 MG), adult high-grade gliomas (D-245 MG, D-54 MG), and medulloblastomas (D425 Med) growing s.c. and i.c. (intracranially) in athymic nude mice. Topotecan was given at a dose of 1.9 mg/kg by i.p. injection in 0.9% saline using a volume of 90 ml/m2 on days 1–5 and 8–12, which represents the dose lethal to 10% of treated animals. Topotecan was active in the therapy of all s.c. xenografts tested, with growth delays ranging from 6.3 days in D-54 MG to 55.7 days in D528 EP. Topotecan produced statistically significant tumor regressions in D425 Med, D-456 MG, D-245 MG, D528 EP, and D612 EP. No tumor regression was seen in any control animal. Statistically significant increases in median survival were seen in the two i.c. xenografts – D-456 MG (28.6% increase) and D-54 MG (39% increase) – treated with topotecan. These studies suggest that topotecan may be an important new addition to the therapy of central nervous system tumors.
|
| Type of Medium: |
Electronic Resource
|
| URL: |
| _version_ | 1798295524581834753 |
|---|---|
| autor | Friedman–, Henry S. Houghton, Peter J. Schold, S. Clifford Keir, Stephen Bigner, Darell D. |
| autorsonst | Friedman–, Henry S. Houghton, Peter J. Schold, S. Clifford Keir, Stephen Bigner, Darell D. |
| book_url | http://dx.doi.org/10.1007/BF00685936 |
| datenlieferant | nat_lic_papers |
| hauptsatz | hsatz_simple |
| identnr | NLM203010094 |
| issn | 1432-0843 |
| journal_name | Cancer chemotherapy and pharmacology |
| materialart | 1 |
| notes | Abstract. The activity of dimethylaminomethyl-10-hydroxycamptothecin (topotecan) was evaluated against a panel of xenografts derived from ependymomas (D528 EP, D612 EP), childhood high-grade gliomas (D-456 MG, D-212 MG), adult high-grade gliomas (D-245 MG, D-54 MG), and medulloblastomas (D425 Med) growing s.c. and i.c. (intracranially) in athymic nude mice. Topotecan was given at a dose of 1.9 mg/kg by i.p. injection in 0.9% saline using a volume of 90 ml/m2 on days 1–5 and 8–12, which represents the dose lethal to 10% of treated animals. Topotecan was active in the therapy of all s.c. xenografts tested, with growth delays ranging from 6.3 days in D-54 MG to 55.7 days in D528 EP. Topotecan produced statistically significant tumor regressions in D425 Med, D-456 MG, D-245 MG, D528 EP, and D612 EP. No tumor regression was seen in any control animal. Statistically significant increases in median survival were seen in the two i.c. xenografts – D-456 MG (28.6% increase) and D-54 MG (39% increase) – treated with topotecan. These studies suggest that topotecan may be an important new addition to the therapy of central nervous system tumors. |
| package_name | Springer |
| publikationsjahr_anzeige | 1994 |
| publikationsjahr_facette | 1994 |
| publikationsjahr_intervall | 8009:1990-1994 |
| publikationsjahr_sort | 1994 |
| publisher | Springer |
| reference | 34 (1994), S. 171-174 |
| search_space | articles |
| shingle_author_1 | Friedman–, Henry S. Houghton, Peter J. Schold, S. Clifford Keir, Stephen Bigner, Darell D. |
| shingle_author_2 | Friedman–, Henry S. Houghton, Peter J. Schold, S. Clifford Keir, Stephen Bigner, Darell D. |
| shingle_author_3 | Friedman–, Henry S. Houghton, Peter J. Schold, S. Clifford Keir, Stephen Bigner, Darell D. |
| shingle_author_4 | Friedman–, Henry S. Houghton, Peter J. Schold, S. Clifford Keir, Stephen Bigner, Darell D. |
| shingle_catch_all_1 | Friedman–, Henry S. Houghton, Peter J. Schold, S. Clifford Keir, Stephen Bigner, Darell D. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts Abstract. The activity of dimethylaminomethyl-10-hydroxycamptothecin (topotecan) was evaluated against a panel of xenografts derived from ependymomas (D528 EP, D612 EP), childhood high-grade gliomas (D-456 MG, D-212 MG), adult high-grade gliomas (D-245 MG, D-54 MG), and medulloblastomas (D425 Med) growing s.c. and i.c. (intracranially) in athymic nude mice. Topotecan was given at a dose of 1.9 mg/kg by i.p. injection in 0.9% saline using a volume of 90 ml/m2 on days 1–5 and 8–12, which represents the dose lethal to 10% of treated animals. Topotecan was active in the therapy of all s.c. xenografts tested, with growth delays ranging from 6.3 days in D-54 MG to 55.7 days in D528 EP. Topotecan produced statistically significant tumor regressions in D425 Med, D-456 MG, D-245 MG, D528 EP, and D612 EP. No tumor regression was seen in any control animal. Statistically significant increases in median survival were seen in the two i.c. xenografts – D-456 MG (28.6% increase) and D-54 MG (39% increase) – treated with topotecan. These studies suggest that topotecan may be an important new addition to the therapy of central nervous system tumors. 1432-0843 14320843 Springer |
| shingle_catch_all_2 | Friedman–, Henry S. Houghton, Peter J. Schold, S. Clifford Keir, Stephen Bigner, Darell D. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts Abstract. The activity of dimethylaminomethyl-10-hydroxycamptothecin (topotecan) was evaluated against a panel of xenografts derived from ependymomas (D528 EP, D612 EP), childhood high-grade gliomas (D-456 MG, D-212 MG), adult high-grade gliomas (D-245 MG, D-54 MG), and medulloblastomas (D425 Med) growing s.c. and i.c. (intracranially) in athymic nude mice. Topotecan was given at a dose of 1.9 mg/kg by i.p. injection in 0.9% saline using a volume of 90 ml/m2 on days 1–5 and 8–12, which represents the dose lethal to 10% of treated animals. Topotecan was active in the therapy of all s.c. xenografts tested, with growth delays ranging from 6.3 days in D-54 MG to 55.7 days in D528 EP. Topotecan produced statistically significant tumor regressions in D425 Med, D-456 MG, D-245 MG, D528 EP, and D612 EP. No tumor regression was seen in any control animal. Statistically significant increases in median survival were seen in the two i.c. xenografts – D-456 MG (28.6% increase) and D-54 MG (39% increase) – treated with topotecan. These studies suggest that topotecan may be an important new addition to the therapy of central nervous system tumors. 1432-0843 14320843 Springer |
| shingle_catch_all_3 | Friedman–, Henry S. Houghton, Peter J. Schold, S. Clifford Keir, Stephen Bigner, Darell D. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts Abstract. The activity of dimethylaminomethyl-10-hydroxycamptothecin (topotecan) was evaluated against a panel of xenografts derived from ependymomas (D528 EP, D612 EP), childhood high-grade gliomas (D-456 MG, D-212 MG), adult high-grade gliomas (D-245 MG, D-54 MG), and medulloblastomas (D425 Med) growing s.c. and i.c. (intracranially) in athymic nude mice. Topotecan was given at a dose of 1.9 mg/kg by i.p. injection in 0.9% saline using a volume of 90 ml/m2 on days 1–5 and 8–12, which represents the dose lethal to 10% of treated animals. Topotecan was active in the therapy of all s.c. xenografts tested, with growth delays ranging from 6.3 days in D-54 MG to 55.7 days in D528 EP. Topotecan produced statistically significant tumor regressions in D425 Med, D-456 MG, D-245 MG, D528 EP, and D612 EP. No tumor regression was seen in any control animal. Statistically significant increases in median survival were seen in the two i.c. xenografts – D-456 MG (28.6% increase) and D-54 MG (39% increase) – treated with topotecan. These studies suggest that topotecan may be an important new addition to the therapy of central nervous system tumors. 1432-0843 14320843 Springer |
| shingle_catch_all_4 | Friedman–, Henry S. Houghton, Peter J. Schold, S. Clifford Keir, Stephen Bigner, Darell D. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts Abstract. The activity of dimethylaminomethyl-10-hydroxycamptothecin (topotecan) was evaluated against a panel of xenografts derived from ependymomas (D528 EP, D612 EP), childhood high-grade gliomas (D-456 MG, D-212 MG), adult high-grade gliomas (D-245 MG, D-54 MG), and medulloblastomas (D425 Med) growing s.c. and i.c. (intracranially) in athymic nude mice. Topotecan was given at a dose of 1.9 mg/kg by i.p. injection in 0.9% saline using a volume of 90 ml/m2 on days 1–5 and 8–12, which represents the dose lethal to 10% of treated animals. Topotecan was active in the therapy of all s.c. xenografts tested, with growth delays ranging from 6.3 days in D-54 MG to 55.7 days in D528 EP. Topotecan produced statistically significant tumor regressions in D425 Med, D-456 MG, D-245 MG, D528 EP, and D612 EP. No tumor regression was seen in any control animal. Statistically significant increases in median survival were seen in the two i.c. xenografts – D-456 MG (28.6% increase) and D-54 MG (39% increase) – treated with topotecan. These studies suggest that topotecan may be an important new addition to the therapy of central nervous system tumors. 1432-0843 14320843 Springer |
| shingle_title_1 | Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts |
| shingle_title_2 | Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts |
| shingle_title_3 | Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts |
| shingle_title_4 | Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts |
| sigel_instance_filter | dkfz geomar wilbert ipn albert fhp |
| source_archive | Springer Online Journal Archives 1860-2000 |
| timestamp | 2024-05-06T09:37:35.085Z |
| titel | Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts |
| titel_suche | Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts |
| topic | WW-YZ |
| uid | nat_lic_papers_NLM203010094 |